Edith P. Mitchell, MD - Jefferson University Hospitals

Edith P Mitchell MD

Jefferson University Physician

Academic Title

Clinical Professor
Director, Center to Eliminate Cancer Disparities
Program Leader, Gastrointestinal Oncology

Specialty

Medical Oncology

Book an Appointment

If you have a Jefferson Health MyChart account you can directly schedule within MyChart.

Contact Us

New or returning patients can complete our secure, online appointment request form. A representative from Jefferson will contact you by email to confirm your appointment.

Request an Appointment

If you'd rather speak with a JEFF NOW® representative, click 1-800-JEFFNOW below. You will then be prompted to enter your phone number.

Call 1-800-JEFFNOW

Overview

Locations

Departments & Programs

Conditions

Treatments

Education & Fellowships

Medical College of Virginia, Medical School
Internship: Meharry Medical College
Residency: Meharry Medical College
Fellowship: Georgetown University Hospital

Years in Practice

Board Certification

Medical Oncology
Internal Medicine

Hospital Affiliation

Thomas Jefferson University Hospitals
Jefferson Methodist Hospital

Insurances Accepted

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Aetna
Aetna Better Health
Aetna Medicare
Aetna PA Employee Benefit Trust Fund (PEBTF)
Amer Assoc Retired Persons (AARP)
AmeriHealth
AmeriHealth Comprehensive
AmeriHealth HMO
AmeriHealth Major Medical
AmeriHealth Personal Choice
Amerihealth Caritas
BC BS Special Care
Blue Choice
Blue Cross/Blue Shield
Blue Cross/Blue Shield of Delaware
Cigna Healthspring
Cigna PPO, POS
Consumer Health Network PPO
CorVel
Coventry/Health America
Delaware Blue Cross/Blue Shield
Devon
Empire BC/BS
Employers Health Network PPO
Evolutions (Guardian Resources)
Federal BCBS
First Health Network
Galaxy
Geisinger Health Plan
Health America PPO
Health Management Network PPO
Horizon Blue Cross/Blue Shield
Horizon HMO
HumanaChoicePPO,Medicare,GoldPlusHMO
Inter-County Health Plan
Intergroup Preferred
Keystone 65 HMO
Keystone First Community HealthChoices
Keystone First VIP Choice
Keystone First VIP Community HealthChoices
Keystone First/Connect
Keystone Health Plan East
Medallion of New Jersey
Medicaid of PA
Medicare
Mercy LIFE
MultiPlan Inc.
NJ Blue Shield
NJ Plus
Oxford of PA
PPO Next
Personal Choice (GPPPN)
Personal Choice 65
PlanCare America
Postal Workers/Mailhandlers
Preferred Care PPO
Premier Blue
Prime Health Services, Inc.
Private Healthcare Systems (PHCS)
Qualcare
Tricare
UPMC Community Health Choices (CHC)
UPMC For Life
UPMC HMO,PPO ReadingHspEmpONLY
UPMC Medicare HMO
US Family Health Plan
United AARP Medicare Complete
United Healthcare

Patient Ratings

Friendliness/courtesy of the care provider:

Explanations the care provider gave you about your problem or condition:

Concern the care provider showed for your questions or worries:

Care provider's efforts to include you in decisions about your treatment:

Information the care provider gave you about medications (if any):

Instructions the care provider gave you about follow-up care (if any):

Degree to which care provider talked with you using words you could understand:

Amount of time the care provider spent with you:

Your confidence in this care provider:

Likelihood of your recommending this care provider to others:

Overall Rating:

Learn more about Patient Ratings

Publications

Pilot Feasibility Study of an Oncology Financial Navigation Program in Brain Cancer Patients

Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome

MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-Bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer

Loss of nuclear localized parathyroid hormone-related protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed STAT5 signaling

Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

The Violence Epidemic in the African American Community: A Call by the National Medical Association for Comprehensive Reform

American Society of Clinical Oncology strategic plan for increasing racial and ethnic diversity in the oncology workforce

Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: A phase II Eastern cooperative oncology group-American college of radiology imaging network cancer research group trial (E3205)

Making the Case for Improving Oncology Workforce Diversity

My crown and glory: Community, identity, culture, and Black women’s concerns of hair product-related breast cancer risk

Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms

African American Patients’ Psychosocial Support Needs and Barriers to Treatment: Patient Needs Assessment

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study

Developing a treatment summary and survivorship care plan responsive to African-American breast cancer survivors

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

Moonshot Toward a Cure for Cancer